



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61F 2/06	A1	(11) International Publication Number: WO 00/48531 (43) International Publication Date: 24 August 2000 (24.08.00)
(21) International Application Number: PCT/US00/04309 (22) International Filing Date: 18 February 2000 (18.02.00) (30) Priority Data: 09/252,333 18 February 1999 (18.02.99) US (71) Applicant: VENPRO [US/US]; Suite 100, 2 Jenner, Irvine, CA 92718 (US). (72) Inventors: QUIJANO, R., C.; 27451 Lost Trail Drive, Laguna Hills, CA 92653 (US). LOYA, Robert; 14178 Mendocino Court, Fontana, CA 92336 (US). (74) Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson and Bear, LLP, 16th Floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: A BIFURCATED BIOLOGICAL PULMONARY VALVED CONDUIT (57) Abstract <p>This invention is a biological prosthesis comprising a pulmonary valved conduit (50) that permits inflow diameters greater than about 22 mm while still maintaining the advantages of a naturally formed biological valved conduit. The vascular prosthetic has an inflow conduit comprising a manifold (52) formed from the sealed attachment (54) of at least two venous valvular conduits (26)(36).</p> <div data-bbox="613 1171 1393 1864"> </div>		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

A BIFURCATED BIOLOGICAL PULMONARY VALVED CONDUIT

Background of the Invention

Pulmonary valved conduits, used to replace diseased arteries such as the pulmonary artery, have been used for the last thirty years. These pulmonary valved conduits have been generally effective at treating pulmonary atresia, pulmonary stenosis, or pulmonary insufficiency. In early embodiments, the conduits consisted of crimped woven or knit polyester tubes housing a valve fabricated from metal components or metal/plastic polymer components. Later valves consisted of metal frames suspending ceramic flat or curved (convex or concave) discs or hemidisks that were passive to the flow of blood exiting the chambers of the heart.

There were at least two disadvantages of these pulmonary valved conduits. First, there was a need to preclot the polyester tubes in order to preclude blood from seeping through the pores of the knit or woven material. Second, after months of usage, a layer of fibrinous material formed in the inner lumen over time from the accumulation of blood proteins. This layer of fibrinous material, referred to as "intimal peel," often separated from the inner wall and interfered with the effective operation of the valve. An ineffective valve required re-operation to replace the conduit and valve, if caught in time. In some instances, if valve replacement came too late, the results were fatal.

In the case of a mechanical valve made of metals and ceramics, there was also the need to continuously medicate the patient with anticoagulants for the duration of his life. That is because no man-made material that is impervious to the clotting effects of blood exists today. Anticoagulation of the patient prevents coagulation of blood on the surfaces of the inner lumen and on the sinuses of the cusps of the valves. Moreover, for children suffering from congenital pulmonary atresia or pulmonary insufficiency, the use of pulmonary valved conduits were not always effective. As the child grew, the prosthetic was less effective due to its inadequate size, requiring frequent replacement. Also, for children especially, anticoagulation requirements are difficult to regiment.

Beginning in the early 1970s, biological valves were used within the crimped polyester conduits to produce a hybrid prosthetic referred to as a biological valved conduit. It was believed that a biological valve, such as a porcine aortic valve fixed with formaldehyde or glutaraldehyde, would eliminate the need for lifetime anticoagulation administration. While the desired result was achieved, there was still the problem of separation of the "intimal peel" from the inner lumen. The intimal peel clogged the leaflets of the biological valve. Moreover, while a porcine aortic valve functioned relatively well as a replacement aortic valve, where the blood pressures from the left ventricle are substantially high (80-120 mmHg), it did not function nearly as effective as a replacement pulmonary valve, where the blood pressures from the right ventricle are quite low (0-15 mmHg). The porcine aortic valve leaflets, which are relatively thick, become substantially less flexible when "fixed" by chemical solutions. Opening at low pressures becomes more difficult. Also, the flow therethrough becomes turbulent, which undesirably promotes the degeneration of the biological material.

The disadvantages mentioned above can be minimized or overcome by using a naturally formed biological conduit which integrates a valve suitable for pulmonary replacement. Preferably, the valve opens and remains open with minimal resistance to the flow of blood at relatively low pressures of less than 1 mm Hg. The valve should also preferably close

under the effect of minimal backflow of blood and be capable of withstanding backflow pressures of up to 200-300 mm Hg. An example of a naturally-formed valvular conduit is described in U.S. Patent No. 5,500,014 to Quijano, et al., the entire specification of which is incorporated herein by reference.

Even this arrangement is limited in that the naturally formed donor conduits have normally minimum diameters of about 22 mm. The largest naturally occurring biological valved conduits are veins with venous valves found in the jugular veins of caprine, cervine, canine, ovine, bovine, equine and other quadruped species and marsupials (e.g., kangaroos and wallabies). While children may be treated effectively with pulmonary valved conduits having such diameters of 22 mm or less, many adolescents and adults require larger-diameter prosthetics. The flow capacity of a pulmonary conduit exiting the right ventricle must be large enough to permit oxygenation of the blood at a sufficient rate to maintain systemic perfusion with blood returning to the heart from the lungs. With normal pulmonary circulation, the blood exiting the right heart through the pulmonary artery (trunk) divides into two separate flows: the right pulmonary artery servicing the right lung, and the left pulmonary artery servicing the left lung. That requires that each lung receive enough flow of blood through each of the two pulmonary arteries emanating from the pulmonary trunk. That flow capacity often requires a diameter greater than the 22 mm found in the jugular veins of donor animals.

Summary of the Invention

The present invention comprises a pulmonary valved conduit that permits inflow diameters greater than about 22 mm while still maintaining the advantages of a naturally-formed biological valved conduit. Specifically, the present invention comprises a vascular prosthetic suitable for replacing a patient's damaged or missing pulmonary valve, said prosthetic comprising an inflow conduit comprising a manifold formed from the sealed attachment of a plurality of donor valved blood vessels, each of said blood vessels housing a biological valve integral therewith, said blood vessels configured to permit the flow of blood therethrough by the valve opening at a relatively low pressure and configured to prevent the backflow of blood therethrough by the valve closing so as to withstand relatively high pressures, said manifold formed upstream of each of the biological valves so as not to interfere with the effective operation of the biological valves, said inflow conduit having a resulting flow capacity following sealed attachment that is larger than the original flow capacity of each of the donor blood vessels, said prosthetic also comprising an outflow conduit positioned downstream of each of the biological valves.

The present invention prosthetic is prepared by using two approximately equal sized (diameter) jugular valved veins obtained from one of the quadrupeds identified above and attaching them in such a fashion to provide a resulting inflow area larger than each of the original donor veins. The inventive manifold does not alter or disturb the configuration of the valve itself. In the preferred embodiment, a bifurcated device is created wherein each of the branches includes its own biological valve flow. Various means of attachment can be used, such as stitching with medical surgical suture, or by means of protein sealants, glues, collages or laser radiation beams. Moreover, the attachment is preferably made so as to minimize the angle of transition of the blood running through the conduit at the site of the bifurcation.

Brief Description of the Drawings

Figure 1 is a cross-section of a venous valvular conduit, showing the valve leaflets in an open position.

Figure 2 is a perspective of two section of venous valvular conduits, indicating where a proposed slicing of the conduits is to be made.

5 Figure 3 is a perspective of the two section of venous valvular conduits of Figure 2, indicating where the slices of the conduits have been made in preparation for attachment.

Figure 4 is a perspective view of the preferred embodiment of the present invention showing how the two venous valved conduits of Figure 2 have been joined.

Figure 5 is a perspective view of a variation of the embodiment of Figure 4 showing a unitary outflow end.

10

Detailed Description of the Preferred Embodiment

With reference to Figure 1, the present invention improves upon the use of a naturally-formed venous valvular conduit 10 consisting of a blood vessel 12 housing a biological valve 14. The valve 14 consists of a plurality of leaflets 16 (two shown) that easily open upon the flow of low pressure blood 18, but closely tightly against a relatively low backpressure of blood; remaining sealed even against backpressures as high as 200-300 mmHg. Such venous valvular conduits may be found, as indicated above, in one of many quadrupeds. Preferably, the donor venous valvular conduit is a section of the jugular vein of a quadruped, the diameters of which approach about 22 mm. While humans have naturally-formed venous valvular conduits, none approach that diameter.

20 With reference to Figures 2-4, the present invention comprises a method of making a vascular prosthetic comprising a valvular conduit suitable for pulmonary valve replacement, wherein the conduit has a diameter greater than 22 mm. The flow output of many human adult right ventricles requires that a pulmonary valve prosthetic have diameters greater than 22 mm to maximize the effectiveness of the prosthetic. With specific reference to Figure 2, the present invention maximizes that benefit by inventively combining two generally-equally-sized donor valvular conduits 20, 30, each having a biological valve 22, 32 housed therewithin. Each conduit 20, 30 has an inflow end 24, 34 and an outflow end 26, 36. The donor valvular conduits are preferably fixed to effectively preserve the conduits in an aldehyde solution; preferably glutaraldehyde, or any other similar solution such as formaldehyde. That entails, for example, soaking the tissue in the aldehyde solution or passing the solution through the valved conduit while immersing the conduit in said solution. Other types of fixation include gamma radiation and polyepoxy compounds. In the preferred embodiment, a slice of the conduits 20, 30 is made where indicated at 28, 38.

25 Referring to Figure 3, the slicing of each conduit 20, 30 results in an angular sectioned inflow end 24, 34 configured to be joined in a manner shown in Figure 4. As shown in Figure 4, the resulting vascular prosthetic 50 comprises an inflow end manifold 52 having a diameter D2. Where the diameter of each donor conduit is D1, the diameter D2 of the resulting prosthetic conduit inflow end manifold 52 is greater than D1. Where it is desired to have a vascular prosthetic with an inflow end diameter greater than 22 mm, the preferred embodiment of the present method comprises

30

attaching two donor valvular conduits having diameters substantially less than about 22 mm in the manner shown in Figures 2 and 3. The resulting diameter D2 will be greater than 22 mm.

As shown in Figure 4, the present invention prosthetic 50 comprises the inflow end manifold 52 having a seam 54 upstream of the two donor biological valves 22, 32. Preferably, to minimize the angle of transition for the blood flow 56, the slice cut from the two donor conduits 20, 30 is made at an angle (1) of less than about 15 , although other angles may be appropriate. The resulting angle (2) of the vascular prosthetic is, therefore, preferably less than 30 , although other angles may be appropriate. Where desired, the resulting prosthetic itself may be preserved via chemical fixation or other type of fixation.

It is contemplated that the attachment of sectioned donor conduits 20, 30 be made via a plurality of stitches made in one or more passes. Preferably, a single pass of stitches is made on the interior to maintain as smooth an inner lumen as possible. Furthermore, it is preferable that each stitch be applied in a manner that said stitches will not unravel when tissue and included neighboring stitches are severed. Discrete stitches may be used. Externally, at least one pass, but preferably two passes, of stitches is applied to reinforce the attachment. Other methods of attachment are also contemplated, including biological and chemical sealants, and laser beam radiation.

With the embodiment of Figure 4, the inflow end 52 may be attached directly to the right ventricle at or about the location of the inflow to the patient's pulmonary trunk. Each outflow end 26, 36 of the prosthetic may be attached to the left and right pulmonary arteries, respectively, thereby bypassing the patient's diseased or missing pulmonary valve. Alternatively, each outflow end 26, 36 could be attached to different locations of the downstream end of the patient's pulmonary trunk, if desired.

With reference to Figure 5, a second embodiment 60 of the present invention is contemplated. The second embodiment 60 comprises an inflow end manifold 62 having a seam 64 and an outflow end manifold 66 having a second seam 68. Where it is desired to have a prosthetic with a single outflow end, the present inventive method further comprises slicing the outflow ends of two donor valvular conduits in the same or similar manner as described above and shown in Figure 3. Performing those steps, the outflow ends of the donor valvular conduits may be attached to form the second outflow end manifold 66 wherein the resulting seam 68 is formed from a plurality of passes of stitches, as described above. This second embodiment 60 may be attached at the inflow end to the right ventricle and at the outflow end to the pulmonary trunk, thereby bypassing the patient's diseased or missing pulmonary valve.

WHAT IS CLAIMED IS:

1. A vascular prosthetic suitable for replacing a patient's damaged or missing pulmonary valve, said prosthetic comprising:

an inflow conduit comprising a manifold formed from the sealed attachment of a plurality of donor valved blood vessels, each of said blood vessels housing a biological valve integral therewith, said blood vessels configured to permit the flow of blood therethrough by the valve opening at a relatively low pressure and configured to prevent the backflow of blood therethrough by the valve closing so as to withstand relatively high pressures, said manifold formed upstream of each of the biological valves so as not to interfere with the effective operation of the biological valves, said inflow conduit having a resulting flow capacity following sealed attachment that is larger than the original flow capacity of each of the donor blood vessels, and

an outflow conduit positioned downstream of each of the biological valves.

2. The prosthetic of Claim 1 wherein said inflow conduit is configured to attach to the patient's heart to receive blood from the right ventricle.

3. The prosthetic of Claim 1 wherein said outflow conduit is configured to attach to the patient's pulmonary artery downstream of the patient's pulmonary valve that is damaged or missing.

4. The prosthetic of Claim 1 wherein the inflow conduit manifold is formed in a manner so that the angle of transition of the blood running therethrough at the inflow conduit manifold is less than about 30°.

5. The prosthetic of Claim 1 wherein the biological valves open at pressures as low as about 1 mm Hg and wherein the biological valves remains sealably closed so as to withstand backflow pressures greater than about 200 mm Hg.

6. The prosthetic of Claim 1 wherein the outflow conduit also has a manifold formed from the sealed attachment of said plurality of valved blood vessels, said outflow conduit manifold formed downstream of said biological valves so as not to interfere with the effective operation of the biological valves, said outflow conduit having a resulting cross-sectional area larger than the original cross-sectional area of each of the blood vessels.

7. The prosthetic of Claim 6 wherein the outflow conduit manifold is formed in a manner so that the angle of transition of the blood running therethrough at the outflow conduit manifold is less than about 30°.

8. The prosthetic of Claim 1 or 6 wherein the outflow conduit is configured to attach to the patient's pulmonary artery at a point downstream of the patient's pulmonary valve that is damaged or missing.

9. The prosthetic of Claim 1 further comprising a second outflow conduit positioned at the downstream side of the biological valves, the second outflow conduit configured to attach to the patient's pulmonary artery at a point downstream of the patient's pulmonary valve that is damaged or missing.

10. The prosthetic of Claim 9 wherein the first outflow conduit is configured to connect to the left pulmonary artery and the second outflow conduit is configured to connect to the right pulmonary artery.

11. The prosthetic of Claim 1 wherein the resulting diameter of said valved conduit is greater than 22 mm.

12. The prosthetic of Claim 11 wherein the resulting diameter of said valved conduit is greater than 28 mm.

13. The prosthetic of Claim 1 wherein the axial seam is made by slicing away a portion of the upstream side of each biological valved blood vessel and suturing the blood vessels together with a single pass of stitches on the interior of said blood vessels so as to maintain a relatively smooth interior lumen surface.

14. The prosthetic of Claim 9 wherein the axial seam is made by slicing away a portion of the downstream side of each biological valved blood vessel and suturing the blood vessels together with a single pass of stitches on the interior of said blood vessels so as to maintain a relatively smooth interior lumen surface.

15. The prosthetic of Claims 13 or 14 wherein the single pass of stitches comprises a plurality of knots.

16. The prosthetic of Claims 13 or 14 wherein the axial seam further comprises a plurality of passes of stitches on the exterior of the blood vessels so as to reinforce the seam.

17. The prosthetic of Claim 1 wherein the biological valved blood vessels each comprise a vein segment.

18. The prosthetic of Claim 17 wherein the biological valved blood vessels each comprise the jugular vein of a donor quadruped or marsupial.

19. The prosthetic of Claim 18 wherein the biological valved blood vessels each comprise the jugular vein of a donor caprine, cervine, canine, ovine, bovine, equine or marsupial.

20. The prosthetic of Claim 1 wherein the inflow conduit results from the splicing of two biological valved blood vessels.

21. The prosthetic of Claim 17 wherein the biological valves are naturally formed within the vein segments.

22. The prosthetic of Claim 21 wherein the biological valves are venous valves.

23. The prosthetic of Claim 1 wherein the biological valves have been fixed.

24. A method of forming a vascular prosthetic that is suitable for implantation within a human to restore pulmonary valvular function, said method comprising the steps of:

extracting first and second vein segments from a biological source, each vein segment having at least one naturally formed venous valve formed therein, each vein segment further having an unvalved portion which is upstream from the at least one venous valve; and

laterally joining the vein segments along the unvalved portions thereof to form an inflow conduit having a cross sectional area that is substantially larger than the cross sectional area of either the first or the second vein segment.

25. The method of Claim 24 further comprising the step of treating the vein segments to preserve the competency of the naturally-formed venous valves.

26. The method of Claim 25 wherein the step of treating the vein comprises fixing the vein with an aldehyde solution.

27. The method of Claim 25 wherein the step of treating the vein comprises using gamma radiation.

28. The method of Claim 25 wherein the step of treating the vein comprises using polyepoxy compounds.

29. A method of treating a damaged or missing pulmonary valve in a patient, said method comprising the steps of using two or more donor, venous, valvular vessels spliced together to form a single vascular prosthetic having an inflow portion that has a cross-sectional area larger than the cross-sectional area of any of said donor venous valvular blood vessels.

5

1/3




FIGURE 1




FIGURE 2

2/3




FIGURE 3




FIGURE 4

3/3




FIGURE 5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/04309

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61F 2/06

US CL : 623/1.24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 623/1.24, 1.26, 2.1, 23.64, 23.68, 915, 916

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST

Search Terms: suturing, blood vessels, valves, joining, attaching, veins

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,609,626 A (QUIJANO et al.) 11 March 1997, col. 5 lines 60-67, and col. 6 lines 3-7 and 9.	24-26, 28, 29
A	US 5,797,930 A (OVIL) 25 August 1998, col. 5 lines 31-34, and Fig. 9.	1-16, 20-22
A	US 4,350,492 A (WRIGHT et al.) 21 September 1982, col. 1 lines 12-17.	1, 23, 27
A	US 3,805,793 A (WRIGHT) 23 April 1974, col. 1 lines 52-54.	1, 17-19

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

17 MAY 2000

Date of mailing of the international search report

29 JUN 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRIAN PELLEGRINO

Telephone No. (703) 306-5899

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)